Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

913 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral glucocorticoids for skin fibrosis in early diffuse systemic sclerosis: a target trial emulation study from the European Scleroderma Trials and Research group database.
Mongin D, Matucci-Cerinic M, Walker UA, Distler O, Becvar R, Siegert E, Ananyeva LP, Smith V, Alegre-Sancho JJ, Yavuz S, Limonta M, Riemekasten G, Rezus E, Vonk M, Truchetet ME, Del Galdo F, Courvoisier DS, Iudici M; EUSTAR collaborators. Mongin D, et al. Arthritis Care Res (Hoboken). 2024 Nov 14. doi: 10.1002/acr.25469. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39542851 Free article.
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.
Wyss A, Jordan S, Graf N, Carreira PE, Distler J, Cerinic MM, Siegert E, Henes J, Zanatta E, Riccieri V, Truchetet ME, Oksel F, Li M, Kucharz EJ, Eyerich K, Del Galdo F, Vonk MC, Vold AH, Gabrielli A, Distler O; EUSTAR collaborators. Wyss A, et al. Arthritis Res Ther. 2024 Oct 31;26(1):187. doi: 10.1186/s13075-024-03418-2. Arthritis Res Ther. 2024. PMID: 39482761 Free PMC article.
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.
Knop S, Szarejko M, Grząśko N, Bringhen S, Trautmann-Grill K, Jurczyszyn A, Vacca A, Khandanpour C, Gamberi B, Pour L, Iversen KF, Stumpp MT, Suter C, Dawson KM, Zitt C, Legenne P, Stavropoulou V, Fey MF, Leupin N, Goldschmidt H. Knop S, et al. Among authors: vacca a. EJHaem. 2024 Aug 1;5(5):940-950. doi: 10.1002/jha2.968. eCollection 2024 Oct. EJHaem. 2024. PMID: 39415900 Free PMC article.
913 results